Share on StockTwits

Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating reaffirmed by research analysts at Investec in a report released on Tuesday. They currently have a GBX 787 ($13.24) target price on the stock. Investec’s price target would suggest a potential upside of 15.35% from the stock’s previous close.

Shares of Dechra Pharmaceuticals plc (LON:DPH) opened at 684.00 on Tuesday. Dechra Pharmaceuticals plc has a 52-week low of GBX 655.00 and a 52-week high of GBX 755.00. The stock’s 50-day moving average is GBX 686.1 and its 200-day moving average is GBX 690.1. The company’s market cap is £596.5 million.

Several other analysts have also recently commented on the stock. Analysts at N 1 Singer reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 760 ($12.78) price target on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 760 ($12.78) price target on the stock. Finally, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 800 ($13.46) price target on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of GBX 771.50 ($12.98).

Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.